<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="0.48.0">
<page number="1" position="absolute" top="0" left="0" height="1262" width="892">
	<fontspec id="0" size="10" family="Times" color="#231f20"/>
	<fontspec id="1" size="16" family="Times" color="#231f20"/>
	<fontspec id="2" size="14" family="Times" color="#231f20"/>
	<fontspec id="3" size="13" family="Times" color="#231f20"/>
	<fontspec id="4" size="14" family="Times" color="#231f20"/>
	<fontspec id="5" size="22" family="Times" color="#231f20"/>
	<fontspec id="6" size="25" family="Times" color="#231f20"/>
	<fontspec id="7" size="7" family="Times" color="#231f20"/>
	<fontspec id="8" size="14" family="Times" color="#231f20"/>
<text top="108" left="106" width="210" height="12" font="0">Archives of the Balkan Medical Union</text>
<text top="122" left="106" width="226" height="12" font="0">Copyright © 2019 Balkan Medical Union</text>
<text top="108" left="635" width="151" height="12" font="0">vol. 54, no. 2, pp. 300-306</text>
<text top="122" left="728" width="59" height="12" font="0">June 2019</text>
<text top="712" left="457" width="12" height="18" font="1">R</text>
<text top="716" left="469" width="43" height="13" font="0">ÉSUMÉ</text>
<text top="747" left="457" width="329" height="19" font="2"><b>Les indicateurs de protéines métalliques (transfer-</b></text>
<text top="766" left="457" width="334" height="19" font="2"><b>rine, céruloplasmine) chez les enfants avec surpoids </b></text>
<text top="784" left="457" width="59" height="19" font="2"><b>et obésité</b></text>
<text top="826" left="457" width="90" height="16" font="3">Introduction. </text>
<text top="822" left="550" width="236" height="19" font="4">Dans tous les pays, on observe une aug-</text>
<text top="841" left="457" width="334" height="19" font="4">mentation progressive du nombre de patients obèses, </text>
<text top="859" left="457" width="333" height="19" font="4">tant chez les adultes que chez les enfants. Aujourd’hui, </text>
<text top="878" left="457" width="329" height="19" font="4">l’obésité est considérée comme une inflammation sys-</text>
<text top="897" left="457" width="334" height="19" font="4">témique chronique de faible activité. Actuellement, il </text>
<text top="916" left="457" width="329" height="19" font="4">existe une accumulation d’informations sur la signifi-</text>
<text top="934" left="457" width="333" height="19" font="4">cation biologique et clinique des protéines métalliques </text>
<text top="953" left="457" width="204" height="19" font="4">dans ce processus inflammatoire.</text>
<text top="976" left="457" width="34" height="16" font="3">But. </text>
<text top="972" left="494" width="293" height="19" font="4">Étudier les effets de la transferrine et de la cé-</text>
<text top="991" left="457" width="328" height="19" font="4">ruloplasmine chez les enfants avec surpoids et obèses.</text>
<text top="712" left="106" width="12" height="18" font="1">A</text>
<text top="716" left="118" width="55" height="13" font="0">BSTRACT</text>
<text top="751" left="106" width="91" height="16" font="3">Introduction. </text>
<text top="747" left="200" width="236" height="19" font="4">A progressive increase of obesity preva-</text>
<text top="766" left="106" width="334" height="19" font="4">lence, both among adults and children, is observed </text>
<text top="784" left="106" width="333" height="19" font="4">in many countries. Today, obesity is seen as a chronic </text>
<text top="803" left="106" width="334" height="19" font="4">systemic inflammation with low activity. Currently, </text>
<text top="822" left="106" width="329" height="19" font="4">new data are available about the biological and clini-</text>
<text top="841" left="106" width="333" height="19" font="4">cal significance of metal proteins in the inflammatory </text>
<text top="859" left="106" width="60" height="19" font="4">processes.</text>
<text top="882" left="106" width="94" height="16" font="3">The objective </text>
<text top="878" left="204" width="232" height="19" font="2"><b>was to study</b> the transferrin and ceru-</text>
<text top="897" left="106" width="318" height="19" font="4">loplasmin indices in overweight and obese children.</text>
<text top="920" left="106" width="155" height="16" font="3">Material and methods. </text>
<text top="916" left="265" width="174" height="19" font="4">We have examined children </text>
<text top="934" left="106" width="333" height="19" font="4">with excess body weight (EBW, 30 children), obesity </text>
<text top="953" left="106" width="333" height="19" font="4">(40 children) and 30 healthy children aged 13-18 years. </text>
<text top="972" left="106" width="333" height="19" font="4">The evaluation included history, anthropometric data </text>
<text top="991" left="106" width="334" height="19" font="4">(height, body weight, body mass index, w aist-to-thigh </text>
<text top="1009" left="106" width="335" height="19" font="4">ratio – WTR), serum glucose, insulin, HOMA-IR </text>
<text top="200" left="608" width="178" height="24" font="5">ORIGINAL PAPER</text>
<text top="311" left="106" width="560" height="27" font="6">INDICES OF METAL PROTEINS (TRANSFERRIN, </text>
<text top="341" left="106" width="488" height="27" font="6">CERULOPLASMIN) IN OVERWEIGHT AND </text>
<text top="371" left="106" width="213" height="27" font="6">OBESE CHILDREN</text>
<text top="423" left="106" width="161" height="17" font="4">Tamila V. SOROKMAN</text>
<text top="422" left="267" width="9" height="10" font="7">1 </text>
<text top="423" left="284" width="182" height="17" font="4">, Snizhana V. SOKOLNYK</text>
<text top="422" left="466" width="6" height="10" font="7">1</text>
<text top="423" left="472" width="234" height="17" font="4">, Alexandra-Maria V. POPELYUK</text>
<text top="422" left="707" width="6" height="10" font="7">2</text>
<text top="423" left="713" width="10" height="17" font="4">, </text>
<text top="441" left="106" width="149" height="17" font="4">Sergii O. SOKOLNYK</text>
<text top="441" left="256" width="6" height="10" font="7">3</text>
<text top="441" left="262" width="164" height="17" font="4">, Olena V. MAKAROVA</text>
<text top="441" left="425" width="6" height="10" font="7">4</text>
<text top="441" left="431" width="173" height="17" font="4">, Volodymyr V. BEZRUK</text>
<text top="441" left="604" width="6" height="10" font="7">5</text>
<text top="466" left="106" width="5" height="11" font="7">1</text>
<text top="465" left="111" width="681" height="19" font="4"> Department of Pediatrics and Medical Genetics, Bukovinian State Medical University, Chernivtsi, </text>
<text top="484" left="106" width="54" height="19" font="4">Ukraine</text>
<text top="503" left="106" width="5" height="11" font="7">2</text>
<text top="503" left="111" width="679" height="19" font="4"> Department of Human Anatomy, “Mykola Turkevich“ Bukovinian State Medical University, Chernivtsi, </text>
<text top="521" left="106" width="54" height="19" font="4">Ukraine</text>
<text top="541" left="106" width="5" height="11" font="7">3</text>
<text top="540" left="111" width="680" height="19" font="4"> Department of Pediatric Surgery and Otolaryngology, Bukovinian State Medical University, Chernivtsi, </text>
<text top="559" left="106" width="54" height="19" font="4">Ukraine</text>
<text top="578" left="106" width="5" height="11" font="7">4</text>
<text top="578" left="111" width="660" height="19" font="4"> Department of Higher Nursing Education, Bukovinian State Medical University, Chernivtsi, Ukraine</text>
<text top="597" left="106" width="5" height="11" font="7">5</text>
<text top="596" left="111" width="680" height="19" font="4"> Department of Pediatrics, Neonatology and Perinatal Medicine, Bukovinian State Medical University, </text>
<text top="615" left="106" width="131" height="19" font="4">Chernivtsi, Ukraine</text>
<text top="634" left="298" width="489" height="19" font="8"><i>Received 07 March 2019, Corrections received 02 May 2019, Accepted 09 May 2019</i></text>
<text top="657" left="550" width="236" height="12" font="0">https://doi.org/10.31688/ABMU.2019.54.2.12</text>
<text top="1079" left="143" width="167" height="13" font="0"> Address for correspondence:  </text>
<text top="1079" left="348" width="116" height="13" font="0"> Tamila V. SOROKMAN</text>
<text top="1096" left="348" width="403" height="13" font="0">Department of Pediatrics and Medical Genetics, Bukovinian State Medical </text>
<text top="1113" left="348" width="53" height="13" font="0">University</text>
<text top="1131" left="348" width="354" height="13" font="0">Address: Prospekt Nezalezhnosti, 98, 58000, Chernivtsi, Ukraine</text>
<text top="1148" left="348" width="306" height="13" font="0">E-mail: t.sorokman@gmail.com; Phone +380506642667</text>
</page>
<page number="2" position="absolute" top="0" left="0" height="1262" width="892">
	<fontspec id="9" size="11" family="Times" color="#231f20"/>
<text top="91" left="552" width="235" height="14" font="9">Archives of the Balkan Medical Union</text>
<text top="1182" left="661" width="42" height="14" font="9">June </text>
<text top="1182" left="693" width="94" height="14" font="9">2019 / 301</text>
<text top="840" left="106" width="5" height="18" font="1">I</text>
<text top="843" left="112" width="85" height="13" font="0">NTRODUCTION</text>
<text top="875" left="136" width="303" height="19" font="4">Obesity is a disease of a particular concern and </text>
<text top="894" left="106" width="334" height="19" font="4">one of the most serious public health problems in </text>
<text top="913" left="106" width="99" height="19" font="4">many countries</text>
<text top="914" left="205" width="11" height="11" font="7">1-3</text>
<text top="913" left="216" width="224" height="19" font="4">. A progressive increase of obesity </text>
<text top="932" left="106" width="335" height="19" font="4">prevalence both among adults and children, has </text>
<text top="951" left="106" width="253" height="19" font="4">been observed in countries such as USA</text>
<text top="952" left="359" width="12" height="11" font="7">4-6</text>
<text top="951" left="372" width="57" height="19" font="4">, Canada</text>
<text top="952" left="428" width="5" height="11" font="7">7</text>
<text top="951" left="432" width="8" height="19" font="4">, </text>
<text top="970" left="106" width="24" height="19" font="4">UK</text>
<text top="971" left="132" width="5" height="11" font="7">8</text>
<text top="970" left="137" width="76" height="19" font="4">,  Denmark</text>
<text top="971" left="214" width="5" height="11" font="7">9</text>
<text top="970" left="218" width="48" height="19" font="4">, India</text>
<text top="971" left="267" width="9" height="11" font="7">10</text>
<text top="970" left="277" width="75" height="19" font="4">,  Australia</text>
<text top="971" left="352" width="9" height="11" font="7">11</text>
<text top="970" left="362" width="74" height="19" font="4">. The com-</text>
<text top="989" left="106" width="333" height="19" font="4">bined prevalence of excess body weight and obesity </text>
<text top="1008" left="106" width="333" height="19" font="4">ranges from 40% in Southern Europe to 10% in </text>
<text top="1027" left="106" width="330" height="19" font="4">Northern Europe. In general, the prevalence of ex-</text>
<text top="1047" left="106" width="333" height="19" font="4">cess body weight is higher in girls (21.1%) compared </text>
<text top="1066" left="106" width="103" height="19" font="4">to boys (18.6%)</text>
<text top="1066" left="209" width="9" height="11" font="7">12</text>
<text top="1066" left="219" width="222" height="19" font="4">. According to official statistics, </text>
<text top="1085" left="106" width="334" height="19" font="4">the average prevalence of obesity among children </text>
<text top="1104" left="106" width="334" height="19" font="4">in Ukraine in 2016 was 13.44 per 1000 children, </text>
<text top="1123" left="106" width="334" height="19" font="4">with variations in the regional aspect from 6.49 in </text>
<text top="1142" left="106" width="333" height="19" font="4">Lugansk and 8.04 in Odesa to 22.87 in Ternopil and </text>
<text top="840" left="457" width="172" height="19" font="4">27.39 in Vinnytsia regions</text>
<text top="840" left="628" width="21" height="11" font="7">13-15</text>
<text top="840" left="649" width="142" height="19" font="4">. The prevalence rate </text>
<text top="859" left="457" width="333" height="19" font="4">of children with excess body weight in Ukraine is </text>
<text top="877" left="457" width="333" height="19" font="4">unknown, as statistical analysis of EBW in Ukraine </text>
<text top="896" left="457" width="109" height="19" font="4">is not conducted</text>
<text top="897" left="566" width="9" height="11" font="7">16</text>
<text top="896" left="575" width="216" height="19" font="4">. However, obesity in children is </text>
<text top="915" left="457" width="329" height="19" font="4">of particular relevance, as it leads to the develop-</text>
<text top="934" left="457" width="334" height="19" font="4">ment of various complications, as well as diseases </text>
<text top="953" left="457" width="334" height="19" font="4">associated with atherogenic dyslipidemia, and may </text>
<text top="972" left="457" width="334" height="19" font="4">be also a risk factor for death in adults, along with </text>
<text top="991" left="457" width="78" height="19" font="4">other causes</text>
<text top="991" left="535" width="20" height="11" font="7">17-19</text>
<text top="991" left="554" width="4" height="19" font="4">.</text>
<text top="1010" left="487" width="304" height="19" font="4">Prevention of obesity in childhood is recognized </text>
<text top="1028" left="457" width="334" height="19" font="4">as one of the main tendency to primary prophylaxis </text>
<text top="1047" left="457" width="334" height="19" font="4">of non-communicable diseases, since adult obesity </text>
<text top="1066" left="457" width="253" height="19" font="4">in most cases originates from childhood</text>
<text top="1067" left="711" width="20" height="11" font="7">20-21</text>
<text top="1066" left="731" width="56" height="19" font="4">. The de-</text>
<text top="1085" left="457" width="334" height="19" font="4">crease of the prevalence of EBW and obesity among </text>
<text top="1104" left="457" width="334" height="19" font="4">adolescents is formalized by an additional indicator </text>
<text top="1123" left="457" width="330" height="19" font="4">of the corresponding target benchmark in the pro-</text>
<text top="1142" left="457" width="195" height="19" font="4">gram document “Health 2020“</text>
<text top="1142" left="652" width="9" height="11" font="7">22</text>
<text top="1142" left="661" width="4" height="19" font="4">.</text>
<text top="130" left="457" width="157" height="16" font="3">Materiel et méthodes. </text>
<text top="126" left="616" width="171" height="19" font="4">Nous avons examiné les en-</text>
<text top="145" left="457" width="335" height="19" font="4">fants en surpoids (IMC, 30 personnes), l’obésité (40 </text>
<text top="164" left="457" width="333" height="19" font="4">personnes) et 30 enfants en bonne santé âgés de 13 à 18 </text>
<text top="182" left="457" width="333" height="19" font="4">ans, incluant: l’anamnèse, l’anthropométrie (taille, poids </text>
<text top="201" left="457" width="334" height="19" font="4">corporel, IMC, ratio OT / OS), le contenu de glucose, </text>
<text top="220" left="457" width="334" height="19" font="4">insuline, calcul HOMA-IR, teneur en transferrine (TF) </text>
<text top="239" left="457" width="329" height="19" font="4">et céruloplasmine (CP). Pour l’analyse statistique des ré-</text>
<text top="257" left="457" width="334" height="19" font="4">sultats, nous avons utilisé les modules des statistiques </text>
<text top="276" left="457" width="329" height="19" font="4">Statistica v.6.0, MedStat et le calculateur SISA en ligne.</text>
<text top="299" left="457" width="74" height="16" font="3">Résultats. </text>
<text top="295" left="534" width="257" height="19" font="4">Sur un échantillon total de 325 NMT, 75 </text>
<text top="314" left="457" width="334" height="19" font="4">enfants (23,1%) présentaient du surpoids et l’obésité a </text>
<text top="332" left="457" width="329" height="19" font="4">été trouvée chez 68 enfants (13,6%). Parmi eux, les gar-</text>
<text top="351" left="457" width="334" height="19" font="4">çons avaient le dessus: 40 (53,3%) d’entre eux étaient </text>
<text top="370" left="457" width="333" height="19" font="4">atteints de DMO et 38 (55,8%) d’obèsité. La teneur </text>
<text top="389" left="457" width="333" height="19" font="4">en TF et en PC chez les enfants âgés de 16 à 18 ans </text>
<text top="407" left="457" width="334" height="19" font="4">était plus élevée (3,90± 0,70 g/L, n = 22, p &lt;0,05). La </text>
<text top="426" left="457" width="334" height="19" font="4">teneur en FT la plus élevée (3,98±0,9 g/L, n = 16) et </text>
<text top="445" left="457" width="334" height="19" font="4">la PC (28,9±0,8, n = 16) ont été enregistrées chez des </text>
<text top="464" left="457" width="329" height="19" font="4">enfants obèses de degré II. Il n’y a pas de différence ap-</text>
<text top="482" left="457" width="333" height="19" font="4">parente entre les indices de TF et de PC et le sexe chez </text>
<text top="501" left="457" width="334" height="19" font="4">les enfants obèses, en association avec la résistance à </text>
<text top="520" left="457" width="333" height="19" font="4">l’insuline et l’obésité sans résistance à l’insuline. On </text>
<text top="539" left="457" width="333" height="19" font="4">observe des changements moins prononcés dans le TF </text>
<text top="557" left="457" width="329" height="19" font="4">et le CP chez les enfants atteints de BMT. La significa-</text>
<text top="576" left="457" width="334" height="19" font="4">tion statistique faible mais élevée de la relation entre </text>
<text top="595" left="457" width="334" height="19" font="4">l’augmentation de l’IMC chez les enfants et la PC et </text>
<text top="614" left="457" width="334" height="19" font="4">le TF (r = 0,28; p &lt;0,001) dans le plasma sanguin des </text>
<text top="632" left="457" width="225" height="19" font="4">enfants obèses (r = 0,23; p &lt;0,0001) .</text>
<text top="655" left="457" width="94" height="16" font="3">Conclusions. </text>
<text top="651" left="554" width="232" height="19" font="4">La détection précoce des enfants at-</text>
<text top="670" left="457" width="329" height="19" font="4">teints de TMN et le suivi de leur santé, y compris l’éva-</text>
<text top="689" left="457" width="335" height="19" font="4">luation des marqueurs inflammatoires systémiques, </text>
<text top="707" left="457" width="334" height="19" font="4">constituent un domaine prometteur et moderne pour </text>
<text top="726" left="457" width="287" height="19" font="4">optimiser le système de prévention de l’obésité.</text>
<text top="768" left="457" width="79" height="16" font="3">Mots-clés: </text>
<text top="764" left="540" width="247" height="19" font="4">enfants, excès de poids, obésité, céru-</text>
<text top="782" left="457" width="151" height="19" font="4">loplasmine, transferrine.</text>
<text top="126" left="106" width="334" height="19" font="4">calculation, transferrin (TF) and ceruloplasmin (CP). </text>
<text top="145" left="106" width="334" height="19" font="4">For statistical analysis of the results, statistic modules </text>
<text top="164" left="106" width="333" height="19" font="4">of Statistica v.6.0, MedStat and on-line SISA calculator </text>
<text top="182" left="106" width="64" height="19" font="4">were used.</text>
<text top="205" left="106" width="62" height="16" font="3">Results. </text>
<text top="201" left="172" width="269" height="19" font="4">In a total sample of 325 children, excess </text>
<text top="220" left="106" width="329" height="19" font="4">body weight was observed in 75 (23.1%) cases and obe-</text>
<text top="239" left="106" width="333" height="19" font="4">sity in 68 (13.6%) children. Boys prevailed, with 40 </text>
<text top="257" left="106" width="334" height="19" font="4">(53.3%) cases of EBW among those and 38 (55.8%) </text>
<text top="276" left="106" width="334" height="19" font="4">with obesity. The content of TF and CP in children </text>
<text top="295" left="106" width="335" height="19" font="4">aged 16-18 years was higher (28.1±0.8 mg/dL and </text>
<text top="314" left="106" width="334" height="19" font="4">3.90±0.70 g/L, n = 22, p &lt;0.05) than in children aged </text>
<text top="332" left="106" width="334" height="19" font="4">13-15 years. The highest TF level (3.98±0.9 g/L, n = </text>
<text top="351" left="106" width="329" height="19" font="4">16) and CP level (28.9±0.8 mg/dL, n = 16) were re-</text>
<text top="370" left="106" width="333" height="19" font="4">corded in children with grade II obesity. There was </text>
<text top="389" left="106" width="334" height="19" font="4">no apparent difference either in the gender indices of </text>
<text top="407" left="106" width="329" height="19" font="4">TF and CP, nor in obese children combined with in-</text>
<text top="426" left="106" width="334" height="19" font="4">sulin resistance or obesity without insulin resistance. </text>
<text top="445" left="106" width="335" height="19" font="4">Less obvious changes in TF and CP were found in </text>
<text top="464" left="106" width="334" height="19" font="4">children with EBW. The weak relationships between </text>
<text top="482" left="106" width="333" height="19" font="4">the increase in BMI in children and the CP and TF (r </text>
<text top="501" left="106" width="334" height="19" font="4">= 0.28; p &lt;0.001) level in the blood plasma of obese </text>
<text top="520" left="106" width="334" height="19" font="4">children (r = 0.23; p &lt;0.0001) were detected, though </text>
<text top="539" left="106" width="233" height="19" font="4">they are highly statistically significant.</text>
<text top="561" left="106" width="94" height="16" font="3">Conclusions. </text>
<text top="557" left="203" width="238" height="19" font="4">Early identification of children with </text>
<text top="576" left="106" width="334" height="19" font="4">EBW and monitoring of their health, including the </text>
<text top="595" left="106" width="333" height="19" font="4">assessment of systemic inflammation markers, is an </text>
<text top="614" left="106" width="329" height="19" font="4">up-to-date and promising area for optimizing the obe-</text>
<text top="632" left="106" width="99" height="19" font="4">sity prophylaxis.</text>
<text top="674" left="106" width="74" height="16" font="3">Keywords: </text>
<text top="670" left="183" width="252" height="19" font="4">children, excess body weight, obesity, ce-</text>
<text top="689" left="106" width="152" height="19" font="4">ruloplasmin, transferrin.</text>
</page>
<page number="3" position="absolute" top="0" left="0" height="1262" width="892">
<text top="91" left="106" width="620" height="14" font="9">Indices of metal proteins (transferrin, ceruloplasmin) in overweight and obese children – SOROKMAN et al</text>
<text top="1182" left="106" width="143" height="14" font="9">302  /  vol. 54, no. 2</text>
<text top="126" left="136" width="300" height="19" font="4">Today, obesity is seen as a chronic systemic in-</text>
<text top="145" left="106" width="330" height="19" font="4">flammation with low activity. Leptin and 12 inflam-</text>
<text top="165" left="106" width="333" height="19" font="4">matory parameters (interleukin [IL]-2, IL-4, IL-6, IL-8, </text>
<text top="184" left="106" width="329" height="19" font="4">IL-10, vascular endothelial growth factor, interfer-</text>
<text top="203" left="106" width="333" height="19" font="4">on-gamma [IFN-], tumor necrosis factor-alpha, IL-1, </text>
<text top="222" left="106" width="333" height="19" font="4">IL-1, monocyte chemotactic protein-1 and epidermal </text>
<text top="241" left="106" width="333" height="19" font="4">growth  factor)  were  measured  from  fasting  blood </text>
<text top="260" left="106" width="48" height="19" font="4">samples</text>
<text top="261" left="154" width="9" height="11" font="7">23</text>
<text top="260" left="163" width="276" height="19" font="4">. Oxidative stress, inflammation and insulin </text>
<text top="280" left="106" width="333" height="19" font="4">resistance are the main culprits of children’s obesity. </text>
<text top="299" left="106" width="333" height="19" font="4">One of the tasks of modern medicine is to find new </text>
<text top="318" left="106" width="330" height="19" font="4">markers that allow to deal with issues of early diag-</text>
<text top="337" left="106" width="334" height="19" font="4">nosis to prevent destructive changes in the body, to </text>
<text top="356" left="106" width="330" height="19" font="4">predict the severity and course of illness, to timely de-</text>
<text top="376" left="106" width="333" height="19" font="4">tect their complications, and foremost to evaluate the </text>
<text top="395" left="106" width="333" height="19" font="4">effectiveness of conservative therapy. The researchers’ </text>
<text top="414" left="106" width="334" height="19" font="4">data show that the information about the biological </text>
<text top="433" left="106" width="333" height="19" font="4">and clinical significance in the inflammation process </text>
<text top="452" left="106" width="330" height="19" font="4">of metal proteins such as ceruloplasmin (in a popula-</text>
<text top="471" left="106" width="281" height="19" font="4">tion of adolescents with metabolic syndrome</text>
<text top="472" left="388" width="9" height="11" font="7">24</text>
<text top="471" left="397" width="43" height="19" font="4">, from </text>
<text top="491" left="106" width="184" height="19" font="4">overweight and obese subjects</text>
<text top="491" left="290" width="9" height="11" font="7">25</text>
<text top="491" left="299" width="140" height="19" font="4">, in insulin-dependent </text>
<text top="510" left="106" width="106" height="19" font="4">diabetes mellitus</text>
<text top="510" left="212" width="21" height="11" font="7">26-28</text>
<text top="510" left="233" width="190" height="19" font="4">, in patients with osteoporosis</text>
<text top="510" left="423" width="9" height="11" font="7">29</text>
<text top="510" left="432" width="8" height="19" font="4">, </text>
<text top="529" left="106" width="123" height="19" font="4">ferritin, transferrin</text>
<text top="530" left="229" width="20" height="11" font="7">30-32</text>
<text top="529" left="250" width="190" height="19" font="4"> is in great demand, as metal </text>
<text top="548" left="106" width="330" height="19" font="4">proteins are blood proteins that take part in deposit-</text>
<text top="567" left="106" width="330" height="19" font="4">ing, transporting and disinfecting metal ions of vari-</text>
<text top="587" left="106" width="333" height="19" font="4">able valency. The importance of the research of the </text>
<text top="606" left="106" width="334" height="19" font="4">proteins lies in their role in the antioxidant system’s </text>
<text top="625" left="106" width="330" height="19" font="4">functioning. Transferrin belongs to the negative pro-</text>
<text top="644" left="106" width="333" height="19" font="4">teins of the acute phase, because its content is reduced </text>
<text top="663" left="106" width="329" height="19" font="4">during inflammation, while ceruloplasmin is a posi-</text>
<text top="682" left="106" width="335" height="19" font="4">tive protein, because its level during inflammation </text>
<text top="702" left="106" width="56" height="19" font="4">increases</text>
<text top="702" left="162" width="20" height="11" font="7">33-34</text>
<text top="702" left="182" width="4" height="19" font="4">.</text>
<text top="742" left="106" width="10" height="18" font="1">T</text>
<text top="746" left="115" width="16" height="13" font="0">HE</text>
<text top="742" left="131" width="5" height="18" font="1"> </text>
<text top="746" left="137" width="64" height="13" font="0">OBJECTIVE</text>
<text top="742" left="201" width="5" height="18" font="1"> </text>
<text top="746" left="207" width="15" height="13" font="0">OF</text>
<text top="742" left="222" width="5" height="18" font="1"> </text>
<text top="746" left="228" width="23" height="13" font="0">THE</text>
<text top="742" left="251" width="5" height="18" font="1"> </text>
<text top="746" left="257" width="39" height="13" font="0">STUDY</text>
<text top="742" left="296" width="5" height="18" font="1"> </text>
<text top="740" left="301" width="134" height="19" font="4">was to evaluate trans-</text>
<text top="759" left="106" width="334" height="19" font="4">ferrin and ceruloplasmin indices in EBW and obese </text>
<text top="778" left="106" width="56" height="19" font="4">children.</text>
<text top="818" left="106" width="16" height="18" font="1">M</text>
<text top="822" left="122" width="49" height="13" font="0">ATERIAL</text>
<text top="818" left="171" width="5" height="18" font="1"> </text>
<text top="822" left="177" width="25" height="13" font="0">AND</text>
<text top="818" left="202" width="5" height="18" font="1"> </text>
<text top="822" left="208" width="59" height="13" font="0">METHODS</text>
<text top="854" left="136" width="305" height="19" font="4">In the study, medical forms 026 / o “Child’s </text>
<text top="873" left="106" width="334" height="19" font="4">medical card“ of 325 children aged 13-18 who were </text>
<text top="892" left="106" width="336" height="19" font="4">treated at Chernivtsi Oblast Children’s Clinical </text>
<text top="911" left="106" width="329" height="19" font="4">Hospital, Ukraine, within 2016-2018, have been ana-</text>
<text top="930" left="106" width="333" height="19" font="4">lyzed. A group of adolescents with EBW (30 children) </text>
<text top="950" left="106" width="334" height="19" font="4">and obesity (40 children) was formed, that made up </text>
<text top="969" left="106" width="334" height="19" font="4">the experimental group. The control group included </text>
<text top="988" left="106" width="333" height="19" font="4">30 healthy adolescents with standard body weight of </text>
<text top="1007" left="106" width="334" height="19" font="4">the same age without complaints, clinical signs and </text>
<text top="1026" left="106" width="334" height="19" font="4">anamnestic data that would indicate the presence of </text>
<text top="1046" left="106" width="125" height="19" font="4">any chronic disease.</text>
<text top="1065" left="136" width="304" height="19" font="4">All studies were conducted after the informed </text>
<text top="1084" left="106" width="329" height="19" font="4">consent was signed by the children and their par-</text>
<text top="1103" left="106" width="334" height="19" font="4">ents. The work follows the ethical principles of the </text>
<text top="1122" left="106" width="334" height="19" font="4">people who act as subjects of the study taking into </text>
<text top="1141" left="106" width="334" height="19" font="4">account the main provisions of the ICH GCR and </text>
<text top="126" left="457" width="336" height="19" font="4">the Helsinki Declaration of the World Medical </text>
<text top="146" left="457" width="329" height="19" font="4">Association for Biomedical Research, where a per-</text>
<text top="165" left="457" width="334" height="19" font="4">son acts as their object (World Medical Association </text>
<text top="185" left="457" width="337" height="19" font="4">Declaration Helsinki 1964, 2000, 2008), The </text>
<text top="204" left="457" width="334" height="19" font="4">Council of Europe Convention on Human Rights </text>
<text top="224" left="457" width="154" height="19" font="4">and Biomedicine (2007).</text>
<text top="243" left="487" width="305" height="19" font="4">The inclusion criteria into the experimental </text>
<text top="263" left="457" width="330" height="19" font="4">group were the presence of EBW or obesity. The ex-</text>
<text top="282" left="457" width="333" height="19" font="4">clusion criteria were: congenital endocrine and renal </text>
<text top="302" left="457" width="334" height="19" font="4">disease, secondary arterial hypertension, prolonged </text>
<text top="321" left="457" width="335" height="19" font="4">hormonal therapy (over 1 month), type 1 diabetes </text>
<text top="341" left="457" width="235" height="19" font="4">mellitus, and patients under 13 years.</text>
<text top="361" left="487" width="303" height="19" font="4">Children were put into 2 age groups: 13-15 years </text>
<text top="380" left="457" width="334" height="19" font="4">old and 16-18 years old. In both groups, history was </text>
<text top="400" left="457" width="335" height="19" font="4">taken, among which anthropometry (height, body </text>
<text top="419" left="457" width="329" height="19" font="4">weight, body mass index – BMI, waist circumfer-</text>
<text top="439" left="457" width="334" height="19" font="4">ence – WC, hip circumference – HC, waist-to-thigh </text>
<text top="458" left="457" width="334" height="19" font="4">ratio (WTR) calculation) and laboratory tests were </text>
<text top="478" left="457" width="329" height="19" font="4">conducted. Verification of obesity and EBW was con-</text>
<text top="497" left="457" width="333" height="19" font="4">firmed according to BMI in percentile tables: BMI in </text>
<text top="517" left="457" width="57" height="19" font="4">the 85-95</text>
<text top="517" left="514" width="8" height="11" font="7">th</text>
<text top="517" left="522" width="268" height="19" font="4"> percentile was considered as excess weight, </text>
<text top="536" left="457" width="333" height="19" font="4">over 95 percent percentile – as obesity, from 5 to 85 </text>
<text top="556" left="457" width="217" height="19" font="4">percentiles as normal body weight.</text>
<text top="575" left="487" width="305" height="19" font="4">Insulin resistance was detected by measuring </text>
<text top="595" left="457" width="329" height="19" font="4">the HOMA index (HOMA-IR). Blood insulin con-</text>
<text top="614" left="457" width="333" height="19" font="4">tent  was  measured  by  radioimmunological  assay </text>
<text top="634" left="457" width="336" height="19" font="4">using Insulin IRMAKIT kits, Beckman Coulter </text>
<text top="653" left="457" width="334" height="19" font="4">(Czech Republic). Blood glucose concentration was </text>
<text top="673" left="457" width="335" height="19" font="4">detected using biosensor electrochemical analysis </text>
<text top="693" left="457" width="335" height="19" font="4">on a SuperGL device (Germany) and Glucocapil </text>
<text top="712" left="457" width="329" height="19" font="4">(Germany) sets. The content of transferrin in se-</text>
<text top="732" left="457" width="329" height="19" font="4">rum was detected by immuno-turbidimetric meth-</text>
<text top="751" left="457" width="336" height="19" font="4">od (TRSF Tina-quant Transferrin ver.2.Roche / </text>
<text top="771" left="457" width="333" height="19" font="4">Hitachi cobas c 311). Serum levels were detected with </text>
<text top="790" left="457" width="335" height="19" font="4">the AssayMax Human Ceruloplasmin ELISA Kit </text>
<text top="810" left="457" width="334" height="19" font="4">(ELISA, Webster, Texas, USA) at the Stat Fax 2100 </text>
<text top="829" left="457" width="139" height="19" font="4">Biochemical Analyzer.</text>
<text top="849" left="487" width="305" height="19" font="4">Statistical analysis of the results (quantitative </text>
<text top="868" left="457" width="334" height="19" font="4">and qualitative analysis with the calculation of the </text>
<text top="888" left="457" width="333" height="19" font="4">average and relative values, identification of statistical </text>
<text top="907" left="457" width="333" height="19" font="4">significance by the 2 criterion for absolute values as </text>
<text top="927" left="457" width="333" height="19" font="4">well as with the Fisher’s angle transformation method </text>
<text top="946" left="457" width="334" height="19" font="4">p for relative values) was conducted with statistical </text>
<text top="966" left="457" width="335" height="19" font="4">modules such as Statistica v.6.0 and MedStat and </text>
<text top="986" left="457" width="333" height="19" font="4">on-line SISA calculator (Simple Interactive Statistical </text>
<text top="1005" left="457" width="334" height="19" font="4">Analysis), using correlation and parametric analysis. </text>
<text top="1025" left="457" width="334" height="19" font="4">Average values are given as (M ± m), where M is the </text>
<text top="1044" left="457" width="333" height="19" font="4">average value of the index, m is the standard error of </text>
<text top="1064" left="457" width="333" height="19" font="4">the mean; n – the number of the experimental group. </text>
<text top="1083" left="457" width="333" height="19" font="4">The estimation of interconnections between different </text>
<text top="1103" left="457" width="333" height="19" font="4">indices was carried out using the correlation analysis </text>
<text top="1122" left="457" width="334" height="19" font="4">with the Pearson’s criterion (rxy). Differences were </text>
<text top="1142" left="457" width="281" height="19" font="4">considered statistically significant at p &lt;0.05.</text>
</page>
<page number="4" position="absolute" top="0" left="0" height="1262" width="892">
	<fontspec id="10" size="13" family="Times" color="#231f20"/>
	<fontspec id="11" size="5" family="Times" color="#231f20"/>
<text top="91" left="552" width="235" height="14" font="9">Archives of the Balkan Medical Union</text>
<text top="1182" left="661" width="42" height="14" font="9">June </text>
<text top="1182" left="693" width="94" height="14" font="9">2019 / 303</text>
<text top="422" left="106" width="12" height="18" font="1">R</text>
<text top="426" left="118" width="44" height="13" font="0">ESULTS</text>
<text top="457" left="136" width="300" height="19" font="4">In the total sample of 325 cases, 75 (23.1%) chil-</text>
<text top="476" left="106" width="334" height="19" font="4">dren with EBW and 68 (13.6%) children with obesity </text>
<text top="495" left="106" width="335" height="19" font="4">were included. Among them, boys prevailed, with </text>
<text top="515" left="106" width="334" height="19" font="4">40 (53.3%) among those with EBW and 38 (55.8%) </text>
<text top="534" left="106" width="334" height="19" font="4">among those with obesity. Analyzing the age of the </text>
<text top="553" left="106" width="329" height="19" font="4">examined patients, EBW and obesity were most com-</text>
<text top="572" left="106" width="333" height="19" font="4">monly recorded among boys aged over 17 years (59.4%) </text>
<text top="591" left="106" width="333" height="19" font="4">and girls aged 15-16 years (64.2%, p&lt;0.05). All obese </text>
<text top="610" left="106" width="333" height="19" font="4">patients had diet violations in anamnestic data. Diet </text>
<text top="629" left="106" width="333" height="19" font="4">violation was found in 25% in the group of adolescents </text>
<text top="648" left="106" width="329" height="19" font="4">without obesity. Indices of BMI, WTR, HOMA-IR in-</text>
<text top="667" left="106" width="333" height="19" font="4">dex, levels of transferrin and ceruloplasmin of patients </text>
<text top="686" left="106" width="256" height="19" font="4">with age correlation are shown in Table 1.</text>
<text top="705" left="136" width="303" height="19" font="4">A difference in the indices of transferrin in obese </text>
<text top="724" left="106" width="333" height="19" font="4">children correlated with age. The higher content of </text>
<text top="743" left="106" width="333" height="19" font="4">transferrin was detected in children aged 16-18 years </text>
<text top="762" left="106" width="333" height="19" font="4">(3.90±0.70 g/L, n = 22, p &lt;0.05). The highest content </text>
<text top="781" left="106" width="333" height="19" font="4">of transferrin was recorded in children with obesity </text>
<text top="800" left="106" width="333" height="19" font="4">grade II – 3.98±0.9 g/L, n = 16 versus 3.05±0.61 g/L, </text>
<text top="819" left="106" width="210" height="19" font="4">n = 24, p &lt;0.05 in children with I</text>
<text top="819" left="317" width="6" height="11" font="7">st</text>
<text top="819" left="323" width="96" height="19" font="4"> degree obesity.</text>
<text top="838" left="136" width="305" height="19" font="4">A similar tendency has been identified in the </text>
<text top="857" left="106" width="334" height="19" font="4">parameters of ceruloplasmin in the blood plasma of </text>
<text top="876" left="106" width="330" height="19" font="4">examined children. Thus, higher values of ceruloplas-</text>
<text top="895" left="106" width="242" height="19" font="4">min were detected in children with II</text>
<text top="895" left="349" width="10" height="11" font="7">nd</text>
<text top="895" left="359" width="77" height="19" font="4"> degree obe-</text>
<text top="914" left="106" width="330" height="19" font="4">sity – 28.9±0.8 mg/dL, n = 16 versus 25.8±0.7 mg/</text>
<text top="933" left="106" width="232" height="19" font="4">dL, n = 24, p &lt;0.05 in children with I</text>
<text top="933" left="338" width="6" height="11" font="7">st</text>
<text top="933" left="344" width="95" height="19" font="4"> degree obesity </text>
<text top="952" left="106" width="333" height="19" font="4">and in children aged 16-18 years – 28.1±0.8 mg/dL, n </text>
<text top="971" left="106" width="334" height="19" font="4">= 22 vs. 19.8±1.2 mg/dL, n = 18, p &lt;0.01) in children </text>
<text top="990" left="106" width="334" height="19" font="4">13-15 year-old. There was not detected a significant </text>
<text top="1009" left="106" width="329" height="19" font="4">difference in the gender ratios of transferrin and ce-</text>
<text top="1028" left="106" width="125" height="19" font="4">ruloplasmin (Fig. 1).</text>
<text top="1047" left="136" width="305" height="19" font="4">Obesity was combined with insulin resistance </text>
<text top="1066" left="106" width="333" height="19" font="4">(HOMA-IR ranged from 2.52 to 2.89 and averaged </text>
<text top="1085" left="106" width="333" height="19" font="4">2.69±0.9) in 18 (45%) children. Moreover, the increased </text>
<text top="1104" left="106" width="334" height="19" font="4">HOMA-IR index was more common in children with </text>
<text top="1123" left="106" width="334" height="19" font="4">grade II obesity. The HOMA-IR index exceeded the </text>
<text top="1142" left="106" width="333" height="19" font="4">norm and averaged 2.78±0.4 in 13 out of 16 children </text>
<text top="422" left="457" width="334" height="19" font="4">with obesity grade II (81.2%), whereas the degree of </text>
<text top="441" left="457" width="333" height="19" font="4">combination with insulin resistance in obese children, </text>
<text top="460" left="457" width="333" height="19" font="4">was found in only 5 children with 24 (20.8%, p&lt;0.01) </text>
<text top="479" left="457" width="284" height="19" font="4">cases with an average HOMA-IR of 2.58 ± 0.2.</text>
<text top="498" left="487" width="305" height="19" font="4">The difference in the values of ceruloplasmin </text>
<text top="517" left="457" width="330" height="19" font="4">and transferrin in obese and insulin-resistant chil-</text>
<text top="536" left="457" width="334" height="19" font="4">dren with obesity without insulin resistance was not </text>
<text top="555" left="457" width="57" height="19" font="4">detected.</text>
<text top="574" left="487" width="304" height="19" font="4">Less pronounced changes in ceruloplasmin and </text>
<text top="593" left="457" width="333" height="19" font="4">transferrin  were  observed  in  children  with  EBW </text>
<text top="611" left="457" width="330" height="19" font="4">(Fig. 2). The levels of metal proteins were within ref-</text>
<text top="630" left="457" width="333" height="19" font="4">erence values in both boys and girls aged 13-15 years. </text>
<text top="649" left="457" width="330" height="19" font="4">However, the indices of ceruloplasmin and transfer-</text>
<text top="668" left="457" width="334" height="19" font="4">rin in children aged 16-18 years had a tendency to </text>
<text top="687" left="457" width="114" height="19" font="4">increase (p&gt; 0.05).</text>
<text top="706" left="487" width="300" height="19" font="4">The correlation analysis revealed a high statisti-</text>
<text top="725" left="457" width="330" height="19" font="4">cal significance of the relationship between the in-</text>
<text top="744" left="457" width="329" height="19" font="4">crease in BMI in children and the values of cerulo-</text>
<text top="763" left="457" width="334" height="19" font="4">plasmin in the blood plasma of obese children (r = </text>
<text top="782" left="457" width="330" height="19" font="4">0.23; p &lt;0.0001) and transferrin (r = 0.28; p &lt;0.001).</text>
<text top="822" left="457" width="12" height="18" font="1">D</text>
<text top="826" left="469" width="65" height="13" font="0">ISCUSSION</text>
<text top="857" left="487" width="303" height="19" font="4">During the last two decades, obesity has emerged </text>
<text top="876" left="457" width="330" height="19" font="4">as a leading public health problem; it is more preva-</text>
<text top="895" left="457" width="329" height="19" font="4">lent in developed countries, affecting adults and chil-</text>
<text top="914" left="457" width="64" height="19" font="4">dren alike</text>
<text top="915" left="521" width="9" height="11" font="7">35</text>
<text top="914" left="531" width="256" height="19" font="4">. Currently, there are no general surveil-</text>
<text top="933" left="457" width="334" height="19" font="4">lance systems in Ukraine that provide comparisons </text>
<text top="952" left="457" width="334" height="19" font="4">of indices and temporary trends in the prevalence </text>
<text top="971" left="457" width="211" height="19" font="4">of EBW and obesity in children</text>
<text top="972" left="668" width="9" height="11" font="7">16</text>
<text top="971" left="678" width="114" height="19" font="4">. The prevalence </text>
<text top="990" left="457" width="335" height="19" font="4">of EBW and obesity among children depends on </text>
<text top="1009" left="457" width="305" height="19" font="4">the sex-age structure of the children population</text>
<text top="1009" left="762" width="20" height="11" font="7">35-36</text>
<text top="1009" left="783" width="8" height="19" font="4">. </text>
<text top="1028" left="457" width="329" height="19" font="4">When planning and conducting work on the preven-</text>
<text top="1047" left="457" width="335" height="19" font="4">tion of obesity among children within the health </text>
<text top="1066" left="457" width="333" height="19" font="4">care in terms of the health care institution, both the </text>
<text top="1084" left="457" width="329" height="19" font="4">sex-age structure of the child population and the pos-</text>
<text top="1103" left="457" width="334" height="19" font="4">sible risks of the development of health disorders in </text>
<text top="1122" left="457" width="333" height="19" font="4">children associated with EBW and obesity should be </text>
<text top="1141" left="457" width="118" height="19" font="4">taken into account</text>
<text top="1142" left="575" width="20" height="11" font="7">37-38</text>
<text top="1141" left="595" width="4" height="19" font="4">.</text>
<text top="123" left="293" width="311" height="17" font="10"><b>Table 1. </b>Indices of BMI, WTR, HOMA-IR index, </text>
<text top="142" left="248" width="398" height="17" font="3">levels of transferrin and ceruloplasmin in the examined children</text>
<text top="191" left="130" width="50" height="15" font="9">Indicator</text>
<text top="166" left="258" width="135" height="15" font="9">Children 13-15 years old</text>
<text top="181" left="308" width="34" height="15" font="9">n = 33</text>
<text top="166" left="497" width="131" height="15" font="9">Children 16-18 yearsold</text>
<text top="181" left="545" width="34" height="15" font="9">n = 37</text>
<text top="184" left="688" width="89" height="15" font="9">Healthychildren</text>
<text top="199" left="715" width="35" height="15" font="9">n = 30</text>
<text top="202" left="251" width="29" height="15" font="9">EBW</text>
<text top="217" left="248" width="35" height="15" font="9">n = 15</text>
<text top="202" left="365" width="42" height="15" font="9">Obesity</text>
<text top="217" left="369" width="34" height="15" font="9">n = 18</text>
<text top="202" left="487" width="29" height="15" font="9">EBW</text>
<text top="217" left="484" width="35" height="15" font="9">n = 15</text>
<text top="202" left="597" width="42" height="15" font="9">Obesity</text>
<text top="217" left="600" width="35" height="15" font="9">n = 22</text>
<text top="237" left="140" width="31" height="15" font="9">WTR</text>
<text top="237" left="233" width="55" height="15" font="9">0.80±0.01</text>
<text top="238" left="287" width="11" height="9" font="11">*,**</text>
<text top="237" left="354" width="53" height="15" font="9">0.93±0.01</text>
<text top="238" left="407" width="11" height="9" font="11">*,**</text>
<text top="237" left="473" width="55" height="15" font="9">0.89±0.03</text>
<text top="238" left="528" width="3" height="9" font="11">*</text>
<text top="237" left="590" width="54" height="15" font="9">0.98±0.01</text>
<text top="238" left="643" width="3" height="9" font="11">*</text>
<text top="237" left="706" width="53" height="15" font="9">0.74±0.02</text>
<text top="258" left="143" width="24" height="15" font="9">BMI</text>
<text top="258" left="240" width="48" height="15" font="9">26.6±0.4</text>
<text top="258" left="287" width="3" height="9" font="11">*</text>
<text top="258" left="358" width="45" height="15" font="9">36.1±1.1</text>
<text top="258" left="403" width="11" height="9" font="11">*,**</text>
<text top="258" left="476" width="48" height="15" font="9">28.9±0.8</text>
<text top="258" left="524" width="3" height="9" font="11">*</text>
<text top="258" left="594" width="45" height="15" font="9">39.7±1.2</text>
<text top="258" left="638" width="3" height="9" font="11">*</text>
<text top="258" left="709" width="47" height="15" font="9">18.8±0.9</text>
<text top="278" left="127" width="56" height="15" font="9">HOMAIR</text>
<text top="278" left="237" width="53" height="15" font="9">2.05±0.11</text>
<text top="279" left="290" width="3" height="9" font="11">*</text>
<text top="278" left="354" width="54" height="15" font="9">2.56±0.10</text>
<text top="279" left="408" width="11" height="9" font="11">*,**</text>
<text top="278" left="474" width="52" height="15" font="9">2.19±0.11</text>
<text top="279" left="526" width="3" height="9" font="11">*</text>
<text top="278" left="590" width="53" height="15" font="9">2.87±0.12</text>
<text top="279" left="643" width="3" height="9" font="11">*</text>
<text top="278" left="706" width="52" height="15" font="9">1.79±0.11</text>
<text top="299" left="127" width="56" height="15" font="9">CP, mg/dl</text>
<text top="299" left="237" width="46" height="15" font="9">16.5±1.1</text>
<text top="299" left="282" width="11" height="9" font="11">*,**</text>
<text top="299" left="359" width="45" height="15" font="9">19.9±1.1</text>
<text top="299" left="403" width="11" height="9" font="11">*,**</text>
<text top="299" left="477" width="47" height="15" font="9">20.5±0.9</text>
<text top="299" left="524" width="3" height="9" font="11">*</text>
<text top="299" left="593" width="47" height="15" font="9">28.1±0.8</text>
<text top="299" left="640" width="3" height="9" font="11">*</text>
<text top="299" left="709" width="47" height="15" font="9">15.4±0.8</text>
<text top="319" left="135" width="40" height="15" font="9">TF, г/л</text>
<text top="319" left="242" width="41" height="15" font="9">1.8±0.6</text>
<text top="320" left="282" width="6" height="9" font="11">**</text>
<text top="319" left="360" width="41" height="15" font="9">2.2±0.8</text>
<text top="320" left="401" width="11" height="9" font="11">*,**</text>
<text top="319" left="480" width="41" height="15" font="9">2.8±0.9</text>
<text top="320" left="521" width="3" height="9" font="11">*</text>
<text top="319" left="596" width="40" height="15" font="9">3.9±0.7</text>
<text top="320" left="636" width="3" height="9" font="11">*</text>
<text top="319" left="713" width="39" height="15" font="9">1.7±0.3</text>
<text top="338" left="106" width="684" height="15" font="9">Notes: WTR –waist-to-thigh ratio; BMI – body mass index; HOMA-IR – index of insulin resistance; EBW – excess body weight; </text>
<text top="353" left="106" width="670" height="15" font="9">CP – ceruloplasmin; TF – transferrin; * – the significance is between the indicators in children with EBW and obesity in con-</text>
<text top="368" left="106" width="653" height="15" font="9">trast to healthy children ** – the values are between the indices in children 13-15 years and children 16-18 years at p &lt;0.05.</text>
</page>
<page number="5" position="absolute" top="0" left="0" height="1262" width="892">
	<fontspec id="12" size="11" family="Times" color="#231f20"/>
<image top="128" left="106" width="676" height="181" src="/export/freefileconvert/10703_f7fc65064382e324a486694a50a8e8fc3e545dee7d4d6d267a350378436ce55e-5_1.png"/>
<image top="361" left="106" width="676" height="309" src="/export/freefileconvert/10703_f7fc65064382e324a486694a50a8e8fc3e545dee7d4d6d267a350378436ce55e-5_2.png"/>
<text top="91" left="106" width="620" height="14" font="9">Indices of metal proteins (transferrin, ceruloplasmin) in overweight and obese children – SOROKMAN et al</text>
<text top="1182" left="106" width="143" height="14" font="9">304  /  vol. 54, no. 2</text>
<text top="729" left="136" width="304" height="19" font="4">According to the results of the study, it can be </text>
<text top="748" left="106" width="334" height="19" font="4">assumed that markers of systemic inflammation can </text>
<text top="767" left="106" width="329" height="19" font="4">be used to predict the development of obesity in chil-</text>
<text top="785" left="106" width="330" height="19" font="4">dren with EBW and assess the obesity status in chil-</text>
<text top="804" left="106" width="29" height="19" font="4">dren</text>
<text top="805" left="136" width="9" height="11" font="7">39</text>
<text top="804" left="145" width="295" height="19" font="4">. The excess of macronutrients in the adipose </text>
<text top="823" left="106" width="329" height="19" font="4">tissues stimulates them to release inflammatory medi-</text>
<text top="842" left="106" width="333" height="19" font="4">ators such as tumor necrosis factor  and interleukin </text>
<text top="860" left="106" width="329" height="19" font="4">6, and reduces production of adiponectin, predispos-</text>
<text top="879" left="106" width="334" height="19" font="4">ing to a pro-inflammatory state and oxidative stress. </text>
<text top="898" left="106" width="334" height="19" font="4">The increased level of interleukin 6 stimulates the </text>
<text top="917" left="106" width="302" height="19" font="4">liver to synthesize and secrete C-reactive protein</text>
<text top="917" left="408" width="21" height="11" font="7">40-41</text>
<text top="917" left="429" width="4" height="19" font="4">.</text>
<text top="935" left="136" width="300" height="19" font="4">On the other hand, the increase of ceruloplas-</text>
<text top="954" left="106" width="329" height="19" font="4">min in obese children can be considered as an an-</text>
<text top="973" left="106" width="334" height="19" font="4">swer to oxidative stress. It is known that there are </text>
<text top="992" left="106" width="329" height="19" font="4">compensatory shifts aimed at increasing the effective-</text>
<text top="1010" left="106" width="333" height="19" font="4">ness of antioxidant protection in obese children. The </text>
<text top="1029" left="106" width="335" height="19" font="4">reasons for such a shift may be an increase in the </text>
<text top="1048" left="106" width="334" height="19" font="4">content of free fatty acids in the blood, as substrates </text>
<text top="1067" left="106" width="334" height="19" font="4">for lipid peroxidation, as well as an increase in the </text>
<text top="1085" left="106" width="329" height="19" font="4">concentration of prooxidant metabolites, in particu-</text>
<text top="1104" left="106" width="333" height="19" font="4">lar catecholamines. The obtained results indicate that </text>
<text top="1123" left="106" width="329" height="19" font="4">insulin resistance does not change or affect the activ-</text>
<text top="1142" left="106" width="309" height="19" font="4">ity of ceruloplasmin and transferrin significantly.</text>
<text top="729" left="457" width="12" height="18" font="1">C</text>
<text top="733" left="469" width="77" height="13" font="0">ONCLUSIONS</text>
<text top="765" left="487" width="300" height="19" font="4">Early detection of children with EBW and moni-</text>
<text top="785" left="457" width="334" height="19" font="4">toring their health, including assessment of systemic </text>
<text top="805" left="457" width="329" height="19" font="4">inflammation markers, is an up-to-date and promis-</text>
<text top="825" left="457" width="333" height="19" font="4">ing area for optimizing the obesity prevention system. </text>
<text top="845" left="457" width="334" height="19" font="4">Emerging changes contribute to the aggravation of </text>
<text top="865" left="457" width="333" height="19" font="4">the disease, especially in puberty. Mechanisms of </text>
<text top="885" left="457" width="330" height="19" font="4">the obesity complications (in particular, insulin re-</text>
<text top="904" left="457" width="334" height="19" font="4">sistance) may be associated with age-related features </text>
<text top="924" left="457" width="333" height="19" font="4">of changes in hormonal secretion in late puberty. </text>
<text top="944" left="457" width="329" height="19" font="4">Identification of the studied markers gains real pros-</text>
<text top="964" left="457" width="334" height="19" font="4">pects for the development of new approaches to the </text>
<text top="984" left="457" width="199" height="19" font="4">treatment of obesity in puberty.</text>
<text top="1047" left="457" width="267" height="15" font="3">Compliance with Ethics Requirements:</text>
<text top="1062" left="487" width="304" height="19" font="8"><i>„The authors declare no conflict of interest regarding </i></text>
<text top="1082" left="457" width="65" height="19" font="8"><i>this article“</i></text>
<text top="1102" left="487" width="300" height="19" font="8"><i>„The authors declare that all the procedures and ex-</i></text>
<text top="1122" left="457" width="334" height="19" font="8"><i>periments of this study respect the ethical standards in the </i></text>
<text top="1142" left="457" width="334" height="19" font="8"><i>Helsinki Declaration of 1975, as revised in 2008(5), as </i></text>
<text top="320" left="262" width="369" height="15" font="12"><b>Fig. 1. </b>Indices of transferrin and ceruloplasmin in obese children.</text>
<text top="672" left="110" width="674" height="15" font="9">Fig. 2. The content of ceruloplasmin and transferrin in blood plasma of children with EBW according to gender (p &lt;0.05).</text>
</page>
<page number="6" position="absolute" top="0" left="0" height="1262" width="892">
	<fontspec id="13" size="11" family="Times" color="#231f20"/>
<text top="91" left="552" width="235" height="14" font="9">Archives of the Balkan Medical Union</text>
<text top="1182" left="661" width="42" height="14" font="9">June </text>
<text top="1182" left="693" width="94" height="14" font="9">2019 / 305</text>
<text top="126" left="106" width="334" height="19" font="8"><i>well as the national law. Informed consent was obtained </i></text>
<text top="145" left="106" width="243" height="19" font="8"><i>from all the patients included in the study“</i></text>
<text top="164" left="136" width="153" height="19" font="8"><i>„No funding for this study“</i></text>
<text top="223" left="106" width="12" height="18" font="1">R</text>
<text top="227" left="118" width="71" height="13" font="0">EFERENCES</text>
<text top="259" left="106" width="333" height="15" font="9">1.  Global status report on noncommunicable diseases 2014. </text>
<text top="275" left="128" width="248" height="15" font="9">Geneva: <i>World Health Organization</i>; 2014, 302 p.</text>
<text top="291" left="106" width="334" height="15" font="9">2.  Centers for Disease Control and Prevention. National </text>
<text top="307" left="128" width="308" height="15" font="9">Center for Health Statistics. Available at: http://www.cdc.</text>
<text top="323" left="128" width="240" height="15" font="9">gov/growthcharts/. (Accessed 17 March 2016).</text>
<text top="339" left="106" width="333" height="15" font="9">3.  Ogden CL, Carroll MD, Fryar CD, Flegal KM. Prevalence </text>
<text top="355" left="128" width="308" height="15" font="9">of obesity among adults and youth: United States, 2011–</text>
<text top="371" left="128" width="204" height="15" font="9">2014. <i>NCHS Data Brief</i>. 2015;(219):1–8.</text>
<text top="387" left="106" width="333" height="15" font="9">4.  Weedn AE, Hale JJ, Thompson DM, Darden PM. Trends </text>
<text top="403" left="128" width="313" height="15" font="9">in obesity prevalence and disparities among low-income </text>
<text top="420" left="128" width="314" height="15" font="9">children in Oklahoma, 2005-2010. <i>Child Obes.</i> 2014; </text>
<text top="436" left="128" width="66" height="15" font="9">10(4):318-25.</text>
<text top="452" left="106" width="329" height="15" font="9">5.  Javed A, Jumean M, Murad MH, et al. Diagnostic perfor-</text>
<text top="468" left="128" width="312" height="15" font="9">mance of body mass index to identify obesity as defined </text>
<text top="484" left="128" width="312" height="15" font="9">by body adiposity in children and adolescents: a systematic </text>
<text top="500" left="128" width="298" height="15" font="9">review and meta-analysis. <i>Pediatr Obes</i>. 2015; 10:234–244.</text>
<text top="516" left="106" width="333" height="15" font="9">6.  Han JC, Lawlor DA, Kimm SY. Childhood obesity. <i>Lancet.</i> </text>
<text top="532" left="128" width="109" height="15" font="9">2010; 375:1737–1748.</text>
<text top="548" left="106" width="330" height="15" font="9">7.  Chaput JP, Lambert M, Gray-Donald K, et al. Short sleep du-</text>
<text top="565" left="128" width="308" height="15" font="9">ration is independently associated with overweight and obe-</text>
<text top="581" left="128" width="308" height="15" font="9">sity in Quebec children. <i>Can J Public Health.</i> 2011;102:369–</text>
<text top="597" left="128" width="21" height="15" font="9">374.</text>
<text top="613" left="106" width="330" height="15" font="9">8.  Upton P, Taylor C, Erol R, Upton D. Family-based child-</text>
<text top="629" left="128" width="312" height="15" font="9">hood obesity interventions in the UK: a systematic review </text>
<text top="645" left="128" width="279" height="15" font="9">of published studies. <i>Community Pract</i>. 2014;87:25–29.</text>
<text top="661" left="106" width="333" height="15" font="9">9.  Harder-Lauridsen NM, Birk NM, Ried-Larsen M, et al. A </text>
<text top="677" left="128" width="308" height="15" font="9">randomized controlled trial on a multicomponent inter-</text>
<text top="693" left="128" width="312" height="15" font="9">vention for overweight school-aged children-Copenhagen, </text>
<text top="710" left="128" width="190" height="15" font="9">Denmark. <i>BMC Pediatr</i>. 2014;14:273.</text>
<text top="726" left="106" width="329" height="15" font="9">10.  Arora M, Nazar GP, Gupta VK, et al. Association of break-</text>
<text top="742" left="128" width="308" height="15" font="9">fast intake with obesity, dietary and physical activity be-</text>
<text top="758" left="128" width="313" height="15" font="9">havior among urban school-aged adolescents in Delhi, </text>
<text top="774" left="128" width="311" height="15" font="9">India: results of a cross-sectional study. <i>BMC Public Health</i>. </text>
<text top="790" left="128" width="69" height="15" font="9">2012;12:881. </text>
<text top="806" left="106" width="333" height="15" font="9">11.  Franklin J, Denyer G, Steinbeck KS, et al. Obesity and risk </text>
<text top="822" left="128" width="308" height="15" font="9">of low self-esteem: a statewide survey of Australian chil-</text>
<text top="838" left="128" width="196" height="15" font="9">dren. <i>Pediatrics</i>. 2006;118:2481–2487. </text>
<text top="855" left="106" width="330" height="15" font="9">12.  Ahrens W, Pigeot I, Pohlabeln H, et al. Prevalence of over-</text>
<text top="871" left="128" width="312" height="15" font="9">weight and obesity in European children below the age of </text>
<text top="887" left="128" width="239" height="15" font="9">10. <i>Int J Obes (Lond)</i>. 2014;38 Suppl 2:S99-107.</text>
<text top="903" left="106" width="329" height="15" font="9">13.  Dudina OO, Moiseienko RO, Zabolotna IE, et al. The dy-</text>
<text top="919" left="128" width="312" height="15" font="9">namics of the health of the children’s population. Annual </text>
<text top="935" left="128" width="312" height="15" font="9">report on the health status of the population, the sanitary </text>
<text top="951" left="128" width="312" height="15" font="9">and epidemiological situation and the results of the health </text>
<text top="967" left="128" width="311" height="15" font="9">system of Ukraine. 2016, Kyiv: <i>Ministry of Health of Ukraine</i>. </text>
<text top="983" left="128" width="59" height="15" font="9">2017:43-69.</text>
<text top="999" left="106" width="333" height="15" font="9">14.  ZelinskaNB, RudenkoNH. Analysis of statistical indicators </text>
<text top="1016" left="128" width="311" height="15" font="9">of the Children’s Endocrinology Service of Ukraine in 2015. </text>
<text top="1032" left="128" width="285" height="15" font="13"><i>Ukrainian Journal of Pediatric Endocrinology</i>. 2016;2:7–17.</text>
<text top="1048" left="106" width="334" height="15" font="9">15. Maidannyk VG, Khaitovych MV, Pavlyshyn HA, et al. </text>
<text top="1064" left="128" width="311" height="15" font="9">Prevalence of excess body weight and high blood pressure </text>
<text top="1080" left="128" width="313" height="15" font="9">among school-children of different regions of Ukraine. </text>
<text top="1096" left="128" width="311" height="15" font="13"><i>International Journal of Pediatrics, Obstetrics and Gynecology</i>. </text>
<text top="1112" left="128" width="88" height="15" font="9">2013;1 (3):33–39.</text>
<text top="1128" left="106" width="333" height="15" font="9">16.  Dyachuk Dmytro D, Zabolotna Iryna E, Yaschenko Yuri B. </text>
<text top="1144" left="128" width="312" height="15" font="9">Analysis of the extension of childhood expectations and </text>
<text top="126" left="478" width="308" height="15" font="9">evaluation of the risks of the development of diseases as-</text>
<text top="142" left="478" width="241" height="15" font="9">sociated with overweight. <i>Wiad Lek.</i> 2018;71:3.</text>
<text top="158" left="457" width="329" height="15" font="9">17.  Rajjo T, Mohammed K, Alsawas M, et al. Treatment of pedi-</text>
<text top="175" left="478" width="311" height="15" font="9">atric obesity: an umbrella systematic review. <i>J Clin Endocrinol </i></text>
<text top="191" left="478" width="131" height="15" font="13"><i>Metab</i>. 2017;102:763–775.</text>
<text top="207" left="457" width="338" height="15" font="9">18.  Sk inner AC, Per rin EM, Moss L A , Skelton </text>
<text top="223" left="478" width="311" height="15" font="9">JA. Cardiometabolic risks and severity of obesity in children </text>
<text top="239" left="478" width="275" height="15" font="9">and young adults. <i>N Engl J Med</i>. 2015;373:1307–1317.</text>
<text top="255" left="457" width="333" height="15" font="9">19.   Reinehr T, Wiegand S, Siegfried W, et al. Comorbidities </text>
<text top="272" left="478" width="311" height="15" font="9">in overweight children and adolescents: do we treat them </text>
<text top="288" left="478" width="212" height="15" font="9">effectively? <i>Int J Obes</i>. 2013; 37:493–499. </text>
<text top="304" left="457" width="333" height="15" font="9">20. Huang JS, Barlow SE, Quiros-Tejeira RE, et al. Childhood </text>
<text top="320" left="478" width="315" height="15" font="9">obesity for pediatric gastroenterologists. <i>J Pediatr </i></text>
<text top="336" left="478" width="188" height="15" font="13"><i>Gastroenterol Nutr</i>. 2013; 56:99–109. </text>
<text top="352" left="457" width="333" height="15" font="9">21.  Prioritizing areas for action in the field of population-based </text>
<text top="369" left="478" width="312" height="15" font="9">prevention of childhood obesity: a set of tools for Member </text>
<text top="385" left="478" width="312" height="15" font="9">States to determine and identify priority areas for action. </text>
<text top="401" left="478" width="242" height="15" font="9">Geneva: <i>World Health Organization</i>; 2012, 86 p.</text>
<text top="417" left="457" width="333" height="15" font="9">22. The European health report 2015. Targets and beyond – </text>
<text top="433" left="478" width="311" height="15" font="9">Reaching new frontiers in evidence. Copenhagen: <i>WHO </i></text>
<text top="449" left="478" width="198" height="15" font="13"><i>Regional Office for Europe</i>; 2015, 150 p.</text>
<text top="466" left="457" width="333" height="15" font="9">23.  Jürimäe J, Võsoberg K, Tamm A-L, Maasalu K, Remmel L, </text>
<text top="482" left="478" width="308" height="15" font="9">Tillmann V. Body composition and inflammatory mark-</text>
<text top="498" left="478" width="311" height="15" font="9">ers  in  pubertal  girls:  Comparison  between  athletes  and </text>
<text top="514" left="478" width="311" height="15" font="9">non-athletic controls. <i>European Journal of Sport Science</i>. 2017; </text>
<text top="530" left="478" width="50" height="15" font="9">17(7):867.</text>
<text top="546" left="457" width="333" height="15" font="9">24. González˝-Jiménez E, Schmidt-Riovalle J, Sinausía L, et al. </text>
<text top="563" left="478" width="311" height="15" font="9">Predictive value of ceruloplasmin for metabolic syndrome in </text>
<text top="579" left="478" width="228" height="15" font="9">adolescents. <i>BioFactors. </i>2016; 42 (2):163-170.</text>
<text top="595" left="457" width="330" height="15" font="9">25.  Safavi SM, Ziaei R, Reza MM. Association of serum cerulo-</text>
<text top="611" left="478" width="312" height="15" font="9">plasmin level with obesity: some components of metabolic </text>
<text top="627" left="478" width="311" height="15" font="9">syndrome and high-sensitive C-reactive protein in Iran. <i>J </i></text>
<text top="643" left="478" width="131" height="15" font="13"><i>Obes</i>. 2012;2012: 951093.</text>
<text top="660" left="457" width="333" height="15" font="9">26.  Cunninghamn  J,  Leffella  M,  Mearklea  P,  Harmatz  P. </text>
<text top="676" left="478" width="308" height="15" font="9">Elevated plasma ceruloplasmin in insulin-dependent diabe-</text>
<text top="692" left="478" width="308" height="15" font="9">tes mellitus: Evidence for increased oxidative stress as a vari-</text>
<text top="708" left="478" width="311" height="15" font="9">able complication. <i>Metabolism – Clinical and Experimental.</i> </text>
<text top="724" left="478" width="114" height="15" font="9">1995;44(8):996 – 999.</text>
<text top="740" left="457" width="333" height="15" font="9">27.  Aguilar  MJ,  González-Jiménez  E,  Antelo  A,  Perona  JS. </text>
<text top="757" left="478" width="312" height="15" font="9">Insulin resistance and inflammation markers: correlations </text>
<text top="773" left="478" width="296" height="15" font="9">in obese adolescents. <i>J Clin Nurs</i>. 2013;22(13-14):2002-10.</text>
<text top="789" left="457" width="330" height="15" font="9">28. Dasari R, Raghunath V. Obesity and type II diabetes mel-</text>
<text top="805" left="478" width="308" height="15" font="9">litus: is resistin the link? <i>J Diabetes Endocr Pract.</i> 2018; 1:1-8.</text>
<text top="821" left="457" width="329" height="15" font="9">29.  Karakas EY, Yetisgin A, Cadirci D, et al. Usefulness of ceru-</text>
<text top="837" left="478" width="312" height="15" font="9">loplasmin testing as a screening methodology for geriatric </text>
<text top="854" left="478" width="308" height="15" font="9">patients with osteoporosis. <i>J Phys Ther Sci</i>. 2016; 28(1):235-9.</text>
<text top="870" left="457" width="333" height="15" font="9">30. Shukla N, Maher J, Masters J, et al. Does oxidative stress </text>
<text top="886" left="478" width="312" height="15" font="9">change ceruloplasmin from a protective to a vasculopathic </text>
<text top="902" left="478" width="215" height="15" font="9">factor? <i>Atherosclerosis.</i> 2006;187(2):238-50.</text>
<text top="918" left="457" width="332" height="15" font="9">31.  Flynn AC, Begum S, White SL, et al. SCOPE and UBPEAT </text>
<text top="934" left="478" width="312" height="15" font="9">Consortiums. Relationships between maternal obesity and </text>
<text top="950" left="478" width="312" height="15" font="9">maternal and neonatal iron status. <i>Nutrients.</i> 2018;10(8). </text>
<text top="967" left="478" width="54" height="15" font="9">Pii:E1000.</text>
<text top="983" left="457" width="333" height="15" font="9">32. Dog˘an G, Andiran N, Çelik N, Uysal S. Iron parameters, </text>
<text top="999" left="478" width="311" height="15" font="9">prohepcidin and soluble transferrin receptor levels in obese </text>
<text top="1015" left="478" width="192" height="15" font="9">children. <i>Minerva Pediatr.</i> 2016;68(6).</text>
<text top="1031" left="457" width="330" height="15" font="9">33.  Halitin S, Deutsch V, Tauman R. Hepcidin, soluble transfer-</text>
<text top="1047" left="478" width="308" height="15" font="9">rin receptor and IL-6 levels in obese children and adoles-</text>
<text top="1064" left="478" width="312" height="15" font="9">cents with and without type 2 diabetes mellitus/impaired </text>
<text top="1080" left="478" width="313" height="15" font="9">glucose tolerance and their association with obstructive </text>
<text top="1096" left="478" width="263" height="15" font="9">sleep apnea. <i>J Endocrinol Invest</i>. 2018;41(8):969-975.</text>
<text top="1112" left="457" width="330" height="15" font="9">34.  KondoK, NoguchiM, MukaiK, et al. Transferrin receptor ex-</text>
<text top="1128" left="478" width="311" height="15" font="9">pression in adenocarcioma of the lung as a histopathologic </text>
<text top="1144" left="478" width="261" height="15" font="9">indicator of prognosis. <i>Chest</i>. 1990;97:1367– 1371.</text>
</page>
<page number="7" position="absolute" top="0" left="0" height="1262" width="892">
<text top="91" left="106" width="620" height="14" font="9">Indices of metal proteins (transferrin, ceruloplasmin) in overweight and obese children – SOROKMAN et al</text>
<text top="1182" left="106" width="143" height="14" font="9">306  /  vol. 54, no. 2</text>
<text top="126" left="106" width="196" height="15" font="9">35.  Krzysztoszek J, Wierzejska E, Zieli</text>
<text top="127" left="303" width="7" height="16" font="0">ń</text>
<text top="126" left="310" width="126" height="15" font="9">ska A. Obesity. An anal-</text>
<text top="142" left="128" width="312" height="15" font="9">ysis of epidemiological and prognostic research. <i>Arch Med </i></text>
<text top="158" left="128" width="98" height="15" font="13"><i>Sci.</i> 2015;11:24–33.</text>
<text top="173" left="106" width="138" height="15" font="9">36.  Kyriazis I,  Rekleiti M,</text>
<text top="174" left="244" width="2" height="9" font="11"> </text>
<text top="173" left="246" width="193" height="15" font="9">Saridi M, et al. Prevalence of obesity </text>
<text top="189" left="128" width="308" height="15" font="9">in children aged 6-12 years in Greece: nutritional behav-</text>
<text top="205" left="128" width="312" height="15" font="9">iour and physical activity. <i>Arch Med Sci</i>. 2012 Nov 9; 8(5): </text>
<text top="221" left="128" width="49" height="15" font="9">859–864.</text>
<text top="236" left="106" width="329" height="15" font="9">37.  Bialo RS , Gordon CM. Underweight, overweight, and pedi-</text>
<text top="252" left="128" width="311" height="15" font="9">atric bone fragility: impact and management. <i>Curr Osteoporos </i></text>
<text top="268" left="128" width="135" height="15" font="13"><i>Rep. </i>2014; 12(3): 319–328.</text>
<text top="126" left="457" width="333" height="15" font="9">38. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of </text>
<text top="142" left="478" width="308" height="15" font="9">childhood and adult obesity in the United States, 2011–</text>
<text top="158" left="478" width="161" height="15" font="9">2012. <i>JAMA.</i> 2014;311:806–14.</text>
<text top="173" left="457" width="330" height="15" font="9">39.  Ellulu SM, Patimah I, Khaza’ai H, et al. Obesity and inflam-</text>
<text top="189" left="478" width="311" height="15" font="9">mation: the linking mechanism and the complications. <i>Arch </i></text>
<text top="205" left="478" width="155" height="15" font="13"><i>Med Sci.</i> 2017; 13(4): 851–863.</text>
<text top="221" left="457" width="337" height="15" font="9">40. Bassuk SS, Rifai N, Ridker PM. High-sensitivit y </text>
<text top="236" left="478" width="315" height="15" font="9">C-reactive  protein:  clinical  importance.  <i>Curr Probl </i></text>
<text top="252" left="478" width="133" height="15" font="13"><i>Cardiol.</i> 2004;29:439–43. </text>
<text top="268" left="457" width="329" height="15" font="9">41.   Lafontan M. Fat cells: afferent and efferent messages de-</text>
<text top="284" left="478" width="312" height="15" font="9">fine new approaches to treat obesity. <i>Annu Rev Pharmacol </i></text>
<text top="299" left="478" width="133" height="15" font="13"><i>Toxicol.</i> 2004; 45:119–46. </text>
</page>
</pdf2xml>
